Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

6.535 +0.225 (+3.57%)
Streaming Delayed Price Updated: 11:32 AM EDT, Jun 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 54,477
Open 6.300
Bid (Size) 6.540 (200)
Ask (Size) 6.590 (300)
Prev. Close 6.310
Today's Range 6.250 - 6.570
52wk Range 3.530 - 8.770
Shares Outstanding 113,793,338
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
From Precision BioSciences, Inc.
Via Business Wire

Performance

YTD
+59.4%
+59.4%
1 Month
-6.1%
-6.1%
3 Month
-5.7%
-5.7%
6 Month
+35.6%
+35.6%
1 Year
+25.9%
+25.9%

More News

Read More
News headline image
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts
From Precision BioSciences, Inc.
Via Business Wire

Frequently Asked Questions

Is Precision BioSciences, Inc. - Common Stock publicly traded?
Yes, Precision BioSciences, Inc. - Common Stock is publicly traded.
What exchange does Precision BioSciences, Inc. - Common Stock trade on?
Precision BioSciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Precision BioSciences, Inc. - Common Stock?
The ticker symbol for Precision BioSciences, Inc. - Common Stock is DTIL on the Nasdaq Stock Market
What is the current price of Precision BioSciences, Inc. - Common Stock?
The current price of Precision BioSciences, Inc. - Common Stock is 6.535
When was Precision BioSciences, Inc. - Common Stock last traded?
The last trade of Precision BioSciences, Inc. - Common Stock was at 06/17/26 11:32 AM ET
What is the market capitalization of Precision BioSciences, Inc. - Common Stock?
The market capitalization of Precision BioSciences, Inc. - Common Stock is 743.64M
How many shares of Precision BioSciences, Inc. - Common Stock are outstanding?
Precision BioSciences, Inc. - Common Stock has 744M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.